











































Minimally invasive and endoscopic versus open necrosectomy
for necrotising pancreatitis: a pooled analysis of individual data
for 1980 patients
Citation for published version:
van Brunschot, S, Hollemans, RA, Bakker, OJ, Besselink, MG, Baron, TH, Beger, HG, Boermeester, MA,
Bollen, TL, Bruno, MJ, Carter, R, French, JJ, Coelho, D, Dahl, B, Dijkgraaf, MG, Doctor, N, Fagenholz, PJ,
Farkas, G, Castillo, CFD, Fockens, P, Freeman, ML, Gardner, TB, Goor, HV, Gooszen, HG, Hannink, G,
Lochan, R, McKay, CJ, Neoptolemos, JP, Oláh, A, Parks, RW, Peev, MP, Raraty, M, Rau, B, Rösch, T,
Rovers, M, Seifert, H, Siriwardena, AK, Horvath, KD & van Santvoort, HC 2018, 'Minimally invasive and
endoscopic versus open necrosectomy for necrotising pancreatitis: a pooled analysis of individual data for
1980 patients', Gut, vol. 67, no. 4, pp. 697-706. https://doi.org/10.1136/gutjnl-2016-313341
Digital Object Identifier (DOI):
10.1136/gutjnl-2016-313341
Link:






Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 17. Aug. 2021
1 
 
 Minimally invasive versus open necrosectomy for necrotizing pancreatitis:  
A systematic review and individual patient data meta-analysis 
short title: Comparison of pancreatic necrosectomy methods 
S. van Brunschot1*, R.A. Hollemans2,3*, O.J. Bakker4, M.G. Besselink2, T.H. Baron5,  H.G. Beger6                              
M.A. Boermeester2, T.L. Bollen7, M.J. Bruno8, R. Carter9, R.M. Charnley10, D. Coelho11, B. Dahl12,             
M.G. Dijkgraaf13, N. Doctor14, G. Farkas15, P.J. Fagenholz16, C. Fernández-del Castillo16, P. Fockens1,     
M.L. Freeman17, T.B. Gardner18, H. van Goor19, H.G. Gooszen20, G. Hannink21, R. Lochan10, C.J. 
McKay9, M.P. Peev16, J.P. Neoptolemos22, A. Oláh23, R.W. Parks24, M. Raraty22, B. Rau25, T. Rösch26, 
M. Rovers20, H. Seifert12, A.K. Siriwardena27, K.D. Horvath28, and H.C. van Santvoort.2,29 
*Both authors contributed equally 
Dept. of Gastroenterology1, Surgery2, and Clinical Research Unit13, Academic Medical Center, Meibergdreef 9, 1105 AZ, 
Amsterdam,The Netherlands 
Dept. of Research and Development3, Surgery29, and Radiology7 St Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, 
The Netherlands 
4Dept. of Vascular Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands 
5Dept. of Gastroenterology and Hepatology, University of North Carolina, 130 Mason Farm Road, 27599-7080, Chapel Hill, NC, 
USA  
6Dept. of Surgery, University of Ulm, Albert-Einstein-Allee 23, D-89081, Ulm, Germany  
8Dept. of Gastroenterology and Hepatology, Erasmus Medical Center, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The 
Netherlands 
9West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, 84 Castle St, G4 0SF, Glasgow, UK 
10Dept. of Surgery, Freeman Hospital, Freeman Road, High Heaton, NE7 7DN, Newcastle upon Tyne, UK 
11Dept. of Surgery, Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Rua Rodolpho Paulo Rocco, 255, Rio 
de Janeiro, Brazil 
12Dept. of Internal Medicine, Oldenburg Municipal Hospital, Rahel-Straus-Straße 10, 26133, Oldenburg, Germany 
14Dept. of Gastrointestinal Surgery, Jaslok Hospital and Research Center, 15 Dr. Deshmukh Marg, 
Pedder Road, 400026, Mumbai, India 
15Dept. of Surgery, University of Szeged, Korányi Fasor 6, 6720, Szeged, Hungary 
16Dept. of Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, MA 02114, Boston, 
Massachusetts, USA 
17Dept. of Gastroenterology, University of Minnesota, 909 Fulton Street, MN 55455, Minneapolis, Minnesota, USA 
18Dept. of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, NH 03756, 
Lebanon, New Hampshire, USA 
Dept. of Surgery19, Operating Rooms - Evidence Based Surgery20, and Orthopaedic Research Lab, Radboud Institute for  Health 
Sciences21, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 GA, Nijmegen, The Netherlands 
2 
 
22Clinical Directorate of General Surgery, National Institutes of Health Research Liverpool Pancreas Biomedical Research  
Unit, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Prescot Street, L7 8XP, Liverpool, UK 
23Dept. of Surgery, Petz-Aladár teaching hospital, Vasvári Pál u. 2-4, 9023, Györ, Hungary  
24Dept. of Surgery, University of Edinburgh, 51 Little France Crescent, Old Dalkeith Road, EH16 4SA, Edinburgh, UK 
25Dept. of Surgery, University of Rostock, Schillingallee 35, 18057, Rostock, Germany 
26Dept. of Interdisciplinary Endoscopy, University Hospital Hamburg-Eppendorf, Martinistrasse 52  
20246, Hamburg, Germany 
27Dept. of Surgery, Manchester Royal Infirmary, Oxford Road, M13 9WL, Manchester, UK 
28Dept. of Surgery, University of Washington, 1959 NE Pacific Streeet, WA 98195, Seattle, USA 
 
Grant support: Dutch Digestive Disease Foundation (funder had no role in study design, data 
collection, analysis or interpretation of study data) 
Correspondence: Hjalmar C van Santvoort, MD, PhD 
Department of Surgery, Academic Medical Center, PO BOX 22660, 1100 DD, Amsterdam, the 
Netherlands 
Department of Surgery, St. Antonius Hospital, PO BOX 2500, 3430 EM, Nieuwegein, the Netherlands 
Dutch Pancreatitis Study Group 
Email: h.vansantvoort@pancreatitis.nl 
Phone: +31616784432  
www.pancreatitis.nl 
Disclosures:  None 
Transcript Profilling: None 
Writing Assistance: None 
Author Contributions: Study concept and design: Bakker, van Brunschot, Besselink, Boermeester, 
Dijkgraaf, Gooszen, Hannink, Horvath, van Santvoort. 
Acquisition of data: Bakker, Besselink, Baron, Beger, Boermeester, Bollen, Bruno, van Brunschot, 
Carter, Charnley, Coelho, Dahl, Doctor, Farkas, Fagenholz, Fernández-del Castillo, Fockens, 
Freeman, Gardner, van Goor, Gooszen, Hollemans, Lochan, McKay, Peev, Neoptolemos, Oláh, 
Parks, Raraty, Rau, Rösch, Seifert, Siriwardena, Horvath, van Santvoort. 
Analysis and interpretation of data: Bakker, van Brunschot, Dijkgraaf, Hannink, Hollemans, Rovers, 
van Santvoort. 
Drafting of the manuscript: Bakker, van Brunschot, Hollemans, Horvath, van Santvoort,  
Critical revision of the manuscript for important intellectual content: all authors. 
Statistical analysis: van Brunschot, Dijkgraaf, Hannink, Hollemans, van Santvoort. 




Background and aims Minimally invasive necrosectomy compared with open necrosectomy might 
improve outcomes in necrotizing pancreatitis, especially in critically ill patients. Evidence from large 
comparative studies is lacking.  
 
Methods We combined individual patient data from 15 published and unpublished cohorts (51 
hospitals; 8 countries) on pancreatic necrosectomy for necrotizing pancreatitis. Death rates were 
compared in patients undergoing open necrosectomy or minimally invasive necrosectomy (i.e. 
minimally invasive surgical or endoscopic necrosectomy). We adjusted for confounding by three types 
of analyses: logistic regression, stratification according to predicted risk of death at baseline (low: 
<5%, intermediate: ≥5% to <15%, high: ≥15% to <35%, and very-high: ≥35%), and propensity-score 
matching.  
 
Results Among 1980 patients with necrotizing pancreatitis, 1167 underwent open necrosectomy, 467 
underwent minimally invasive surgical necrosectomy, and 346 underwent endoscopic necrosectomy. 
There was a lower risk of death for minimally invasive surgical necrosectomy (odds ratio, 0.53; 95%-
CI, 0.34 to 0.84; P=0.006) and endoscopic necrosectomy (odds ratio, 0.19; 95%-CI, 0.06 to 0.61; 
P=0.005). After risk stratification and propensity-score matching, minimally invasive surgical 
necrosectomy remained associated with a lower risk of death than open necrosectomy in the very-
high-risk group (42/111 versus 59/111; risk ratio, 0.70; 95%-confidence interval, 0.52 to 0.95; P=0.02). 
Endoscopic necrosectomy was associated with a lower risk of death than open necrosectomy in the 
high-risk group (3/40 versus 12/40; risk ratio, 0.27; 95%-CI, 0.08 to 0.88; P=0.03) and in the very-high-
risk group (12/57 versus 28/57; risk ratio, 0.43; 95%-CI, 0.24 to 0.77; P=0.005). 
 
Conclusions In high-risk patients with necrotizing pancreatitis, minimally invasive surgical and 
endoscopic necrosectomy reduced death rates compared with open necrosectomy. 





Approximately 20% of patients with acute pancreatitis develop necrosis of the pancreas and 
peripancreatic tissue.1 These patients have a prolonged disease course with a high risk of 
complications such as multiple organ failure, secondary infection of the necrosis, and death.1,2 Many 
patients with necrotizing pancreatitis ultimately need to undergo pancreatic necrosectomy.1-4 
Death rates after pancreatic necrosectomy recently reported by international expert centers vary from 
0% to 25%.5-12 This variation may be explained by differences in case-mix or by differences in 
treatment strategies. Several changes in the treatment of patients with necrotizing pancreatitis have 
occurred over the last 20 years. First, the timing of intervention has shifted from very early in the 
disease course to around 3-4 weeks after onset of symptoms.3,4,13 Second, the indication for 
necrosectomy has changed from sterile necrosis to predominantly infected necrosis.3,4,14 Third, 
catheter drainage is now often the first step in treatment before necrosectomy.15 Finally, as an 
alternative to open necrosectomy, minimally invasive necrosectomy (i.e. minimally invasive surgical 
necrosectomy and endoscopic necrosectomy) is increasingly being performed.7-10,12 
Minimally invasive necrosectomy is thought to be beneficial by inducing less surgical stress, thereby 
lowering the pro-inflammatory response, especially in already critically ill patients.16,17 Studies that 
directly compare minimally invasive necrosectomy with open necrosectomy for clinical outcomes are 
lacking. A few retrospective studies have been performed but these were mostly small and hampered 
by selection bias and confounding.12,18 The only available randomized trial included only 20 patients.17 
Because necrotizing pancreatitis is a complex and relatively rare disease, it is unlikely that a trial with 
a sufficiently large sample size to study mortality will ever be performed. It therefore remains unclear if 
minimally invasive necrosectomy reduces death rates, especially in the context of other recent 
changes in the treatment of necrotizing pancreatitis. As a result, open necrosectomy remains a valid 
option and is still practiced worldwide.3,11,19,20 
In this international collaborative project we combined individual patient data from published and 
unpublished cohorts on pancreatic necrosectomy in expert centers worldwide. We compared death 
rates of open necrosectomy with minimally invasive necrosectomy in a large number of patients, which 
allowed several approaches to adjust for confounding. We hypothesized that minimally invasive 





We combined data from patients undergoing pancreatic necrosectomy in 51 hospitals who were 
included in 15 cohorts from expert pancreatic centers in the United States and Canada (n=4), The 
United Kingdom (n=4), Germany (n=2), Hungary (n=2), The Netherlands (n=1), India (n=1), and Brazil 
(n=1). The cohorts were identified by a predefined systematic literature search. A total of 13 cohorts 
were published previously.6-10,19,21-27 For 4 of these cohorts7,10,19,24 additional patients were included of 
whom the data were unpublished and two cohorts consist of entirely unpublished data. Details on the 
search, eligibility criteria,  included cohorts and quality assessment/risk of bias of individual studies are 
available in the appendix (p 4). Once the corresponding author of a cohort agreed to participate, 
original and additional individual patient data regarding baseline characteristics, method of 
intervention, and clinical outcomes were collected. All data were anonymized. The Institutional review 
boards of the participating centers approved study protocols, if appropriate. The study design was 
predefined and prospectively registered (www.crd.york.ac.uk/PROSPERO: CRD42014008995). We 
adhered to the MOOSE guidelines for reporting meta-analyses of observational cohort studies and the 
PRISMA-IPD guidelines for meta-analysis of individual participant data.28,29 
 
Data collection 
Data were collected in a standardized manner using an electronic case record form for the following 
baseline variables: sex, age, tertiary referral, cause of pancreatitis, catheter drainage before 
necrosectomy, time from hospital admission to necrosectomy, APACHE-II score and organ failure ≤24 
hours before necrosectomy, documented infection of necrosis, and year of necrosectomy. Method of 
necrosectomy (i.e. open necrosectomy, minimally invasive surgical necrosectomy or endoscopic 
necrosectomy), complications, and death were also recorded. Detailed definitions are provided in the 
appendix (p 5). Data were checked for consistency and plausibility. Data were missing in eight of the 
13 baseline variables,  with a range of 0.2% to 4.7%. Missing data were imputed by multiple 
imputation using chained equations. More information on missing data and imputation is available in 





Patients undergoing open necrosectomy were compared with patients undergoing minimally invasive 
surgical necrosectomy and with patients undergoing endoscopic necrosectomy. The primary end point 
was in-hospital death during index admission. Readmissions within 10 days after discharge from index 
admission were considered as part of the index admission. We anticipated that certain prognostic 
baseline variables that are associated with death, such as measures of disease severity, would not be 
evenly distributed among treatment groups. This could be due to selection bias in the individual 
cohorts or because clinical severity played a role in deciding which method of necrosectomy was 
performed (i.e. confounding by indication or confounding by severity).30 To adjust for these and other 
forms of confounding, we performed three types of analyses. 
First, the association between different methods of necrosectomy and death was evaluated using 
multivariable logistic regression. The following potential confounding factors were included as 
covariates, if associated with death in univariable analysis (P<0.1): study cohort, sex, age, tertiary 
referral, cause of pancreatitis, year of necrosectomy, previous catheter drainage, APACHE-II score, 
cardiovascular failure, pulmonary failure, renal failure, documented infected necrosis, and time since 
hospital admission. Variables were excluded using stepwise backward elimination (P>0.05). 
Second, patients were stratified according to their predicted risk of death at baseline. The aim of this 
approach was twofold: 1) to study the effect of necrosectomy in different subgroups of disease severity 
because it was anticipated that the beneficial effect of minimally invasive necrosectomy is greater in 
more severely ill patients; and 2) to adjust for differences in disease severity between the groups of 
open necrosectomy and minimally invasive surgical necrosectomy or endoscopic necrosectomy which 
could have occurred due to selection. A prediction model for the risk of death determined at baseline 
(i.e. within 24 hours before necrosectomy) was developed using the data from patients undergoing 
open necrosectomy (i.e. the control group).31 The model was based on known parameters for disease 
severity as a result of pancreatitis and for pre-existing co-morbidity, and included the following 
predictors: study cohort, age, APACHE-II score, cardiovascular failure, pulmonary failure, and renal 
failure. Performance of the model was very good with an area under the curve of 0.85. We chose this 
method as opposed to classifying severity by the recently revised Atlanta classification1 or the 
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determinant-based classification of acute pancreatitis severity32 because we specifically wanted to 
determine disease severity at the time of necrosectomy, in contrast with severity of pancreatitis in 
general. 
Using this model, patients in each treatment group were assigned to one of four baseline categories of 
predicted risk of death: low (<5%); intermediate (≥5% to <15%); high (≥15% to <35%); or very high 
(≥35%). Further details on the prediction model and risk stratification are available in the appendix (p 
6-7). In each risk group, patients undergoing open necrosectomy were compared with patients 
undergoing minimally invasive surgical necrosectomy and with patients undergoing endoscopic 
necrosectomy. 
Third, and building on the second analysis, patients in each risk group were matched using their 
propensity-score to achieve cohorts of patients with similar baseline characteristics. The propensity-
score is the probability of treatment assignment conditional on observed baseline characteristics and 
allows one to design and analyze an observational study so that it mimics some of the characteristics 
of a randomized trial.33 We developed a non-parsimonious multivariable logistic regression model to 
estimate a propensity-score for minimally invasive surgical necrosectomy and endoscopic 
necrosectomy. Details of the individual variables included in the model are provided in the appendix (p 
7). Patients undergoing minimally invasive surgical necrosectomy or endoscopic necrosectomy were 
matched 1:1 with patients undergoing open necrosectomy using their propensity-score with the 
nearest-neighbour-matching algorithm without replacement (a caliper width equal to 0.2 of the 
standard deviation of the logit score was used). Standardized differences were estimated for all the 
baseline covariates to assess imbalance before matching and balance after matching. A standardized 
difference of less than 10% indicates appropriate balance.33 
Results of multivariable regression analysis are given as odds ratios and 95%-confidence intervals 
(CI). Differences in death rates were tested with the chi-square test in the unmatched cohorts and with 
the McNemar’s test for paired data in the matched cohorts. Comparisons of death rates are presented 




Predefined subgroup analyses were performed for patients with infected necrosis and for patients who 





We included 1980 patients who underwent pancreatic necrosectomy; a total of 1167 underwent open 
necrosectomy, 467 patients underwent minimally invasive surgical necrosectomy, and 346 underwent 
endoscopic necrosectomy. Baseline characteristics for the entire study population and per study 
cohort are presented in the appendix (pp 14-16). A total of 325 out of 1980 patients (16%) in the study 
died.  
  
Logistic regression adjusted-analysis 
The following baseline characteristics (i.e. within 24 hours before necrosectomy) were associated with 
death in multivariable regression analysis: study cohort, year of necrosectomy, age, APACHE-II score, 
cardiovascular failure, pulmonary failure, and renal failure (appendix pp 18). While adjusting for these 
potential confounders, minimally invasive surgical necrosectomy and endoscopic necrosectomy 
remained associated with a lower risk of death: odds ratio 0.53 (95%-CI, 0.34 to 0.84); P=0.006 and 
odds ratio 0.19 (95%-CI, 0.06 to 0.61); P=0.005, respectively. 
 
Baseline death risk–stratified-analysis 
Using a multivariable prediction model (appendix p 19), patients were stratified according to their 
predicted risk of death at baseline. Stratification was considered successful because there were no 
major differences in predicted risk of death for patients undergoing open necrosectomy, minimally 
invasive surgical necrosectomy, and endoscopic necrosectomy, respectively: low-risk group: median 
2% ([interquartile range (IQR)], 1% to 3%) vs. median 3% (IQR, 0% to 4%) vs. median 4% (IQR, 2% to 
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4%); intermediate-risk group: median 9% (IQR, 7% to 11%) vs. median 9% (IQR, 7% to 12%) vs. 
median 10% (IQR, 8% to 12%); high-risk group: median 24% (IQR, 18% to 29%) vs. median 22% 
(IQR, 19% to 29%) vs. median 22% (IQR, 19% to 27%); very high-risk group: median 52% (IQR, 43% 
to 64%) vs. median 58% (IQR, 45% to 78%) vs. 51% (IQR, 42% to 72%). 
Baseline characteristics in each risk group are presented in Tables 1 and 2. Even though the predicted 
risk of death rates were comparable among treatment groups, some imbalance for individual baseline 
characteristics remained, as indicated by standardized mean differences greater than 10%.  
Actual death rates in each risk group are shown in Figure 1. In the higher risk groups, fewer patients 




A total of 376 patients who underwent minimally invasive surgical necrosectomy were matched with 
376 patients who underwent open necrosectomy and a total of 198 patients who underwent 
endoscopic necrosectomy were matched with 198 patients who underwent open necrosectomy. The 
matched cohorts were well balanced for all baseline characteristics because none of the standardized 
differences exceeded 10% (Tables 1 and 2). 
Actual death rates in the matched cohorts in each risk group are shown in Figure 1. Minimally invasive 
surgical necrosectomy was associated with a lower risk of death than open necrosectomy in the very 
high-risk group; risk ratio 0.70 (95%-CI, 0.52 to 0.95); P=0.02. Endoscopic necrosectomy was 
associated with a lower risk of death than open necrosectomy in the high-risk group: risk ratio 0.27 
(95%-CI, 0.08 to 0.88); P=0.03; and the very high-risk group: risk ratio 0.43 (95%-CI, 0.24 to 0.77); 
P=0.005; with judgment suspended in the intermediate-risk group: risk ratio 0.14 (95%-CI, 0.02 to 
1.10); P=0.06. 
 
Subgroup and sensitivity analyses 
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The baseline death risk–stratified analysis and propensity-score matched–analysis were also 
performed in the subgroups of patients with documented infected necrosis (403 patients [86%] in the 
minimally invasive surgical group, 197 patients [57%] in the endoscopic group and 885 patients [76%] 
in the open necrosectomy group) and in patients who underwent previous catheter drainage (436 
patients [93%] in the minimally invasive surgical group, 178 patients [51%] in the endoscopic group 
and 210 patients [18%] in the open necrosectomy group). Baseline characteristics for the matched and 
the unmatched cohorts and their actual death rates are provided in the appendix (pp 20-35). Results 
were in line with the primary analyses. 
As alternative risk stratification, patients were stratified according to their APACHE-II score within 24 
hours before necrosectomy (i.e. <7, ≥7 to <11, ≥11 to <15, and ≥15) and matched with propensity-
score matching (appendix pp 36-41). Similar to the primary analyses, minimally invasive surgical 
necrosectomy and endoscopic necrosectomy were associated with a lower actual death rate in the 
higher APACHE-II groups (appendix pp 42-43).  
In addition to death, other study outcomes included postoperative complications (i.e. bleeding and 
pancreatic fistula), number of necrosectomies, and hospital stay after necrosectomy. In the matched 
cohorts, bleeding occurred in 5 - 19% of patients and was more frequent in the higher risk of death 
groups. There was no statistically significant difference between minimally invasive necrosectomy 
methods and open necrosectomy. Pancreatic fistula occurred in 4 - 35% of patients, was more 
frequent in patients at lower risk of death and occurred more often in patients who underwent open 
necrosectomy. Overall, patients who underwent minimally invasive surgical necrosectomy had the 
longest hospital stay after necrosectomy (median 32 - 54 days), followed by open necrosectomy 
(median 21 - 52 days) and endoscopic necrosectomy (5 - 42 days). The number of necrosectomies 
was highest in the endoscopic groups (median 3 - 4), followed by the minimally invasive surgical 
groups (median 2 -3) and open necrosectomy groups (median 1). Detailed results with respect to 
these outcomes for the unmatched cohorts and matched cohorts in each risk group are provided in the 




In this international collaborative study involving 1980 patients with necrotizing pancreatitis from 51 
hospitals across eight countries, minimally invasive surgical necrosectomy or endoscopic 
necrosectomy compared with open necrosectomy significantly decreased mortality among high-risk 
patients. This benefit of minimally invasive techniques remained apparent after adjustment for 
confounding by several different analyses. 
A large number of, mostly retrospective, cohort studies have reported outcomes of patients 
undergoing minimally invasive pancreatic necrosectomy. Few studies, however, have directly 
compared minimally invasive necrosectomy with open necrosectomy. One meta-analysis of four 
studies compared 215 patients undergoing minimally invasive surgical necrosectomy with 121 patients 
undergoing open necrosectomy.18 Mortality was 17% after minimally invasive surgical necrosectomy 
vs. 30% after open necrosectomy (odds ratio 0.43; 95%-CI, 0.01-8.60; P=0.06). This meta-analysis, 
however, suffered from significant heterogeneity. Another single center study compared 274 patients 
undergoing minimally invasive surgical necrosectomy with 120 patients undergoing open 
necrosectomy; mortality was 15% vs. 23% (P = 0.06).12 Our study, with individual patient data, differed 
from these earlier studies because of its much larger sample size and, as a consequence, the 
possibility to analyze different risk groups and to adjust for the effects of confounding and selection 
bias. 
How can the lower death rates after minimally invasive necrosectomy be explained? It is well known 
that, in various diseases, minimally invasive surgical techniques induce less surgical stress and 
thereby lead to a lower systemic pro-inflammatory response as compared with open surgery.34,35 This 
was also demonstrated in necrotizing pancreatitis: in the only randomized trial that compared 
endoscopic necrosectomy with surgical necrosectomy (a total of 20 patients), endoscopic 
necrosectomy reduced the levels of the pro-inflammatory cytokine interleukin (IL)-6 during the 7 days 
after the procedure.17 The more pronounced pro-inflammatory response invoked by open 
necrosectomy may facilitate organ failure or worsen pre-existing organ failure, especially in patients 
who are already suffering from a severe inflammatory condition such as necrotizing pancreatitis.15 This 
seems of particular importance because organ failure is the main determinant for mortality in patients 
with necrotizing pancreatitis, especially in the presence of infected necrosis.36 The same trial that 
demonstrated lower levels of IL-6 after endoscopic necrosectomy also showed lower rates of post-
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procedure multiple organ failure.17 A reduction in multiple organ failure with less surgical stress was 
also seen in another randomized trial that compared primary catheter drainage with open 
necrosectomy in 88 patients with necrotizing pancreatitis.15 In contrast with these previous trials,15,17 
we did not study the rate of organ failure as a surrogate outcome. Our study was designed to evaluate 
the most relevant clinical endpoint of mortality, with a sufficiently large number of patients, even in the 
subgroups of the most severely ill patients. The concept of lowering mortality by reducing the pro-
inflammatory response by limiting surgical stress in already critically ill patients is not new. It is also the 
rationale for the well-established concept of ‘damage control surgery’ in trauma patients.37 Similar to 
patients with necrotizing pancreatitis, these patients suffer from a systemic inflammatory response as 
a result of multiple injuries.38 Several studies have shown that early extensive orthopedic trauma 
surgery acts as ‘a second hit’ that induces pro-inflammatory cytokines and multiple organ failure.39 To 
lower mortality in trauma patients early surgical intervention therefore only consists of short duration, 
life-saving operations (e.g. to control for bleeding), whereas lengthy fracture repairs are performed at a 
later stage when the systemic inflammatory state has subsided and the patient is able to sustain the 
extensive operative burden.37,39 
Our results suggest that patients with necrotizing pancreatitis who are severely ill should undergo 
minimally invasive surgical or endoscopic necrosectomy instead of open necrosectomy, given the 
expertise in these minimally invasive techniques is available. In the propensity score matched 
analysis, we did not find significantly lower death rates in the low- and intermediate-risk groups. These 
patients, who are in a relatively stable clinical condition, seem capable of sustaining the larger surgical 
stress and pro-inflammatory hit induced by open necrosectomy. Another explanation may be that, due 
to their lower a priori risk of death, the subgroup of less severely ill patients was too small to detect a 
difference in death between methods of necrosectomy. This is supported by the wide 95%-confidence 
intervals observed in these groups (Figure 1). One could therefore argue that open necrosectomy is 
still a reasonable treatment option in these patients. However, other reasons to prefer minimally 
invasive necrosectomy techniques are lower rates of pancreatic fistula as shown in our study and 
lower rates of long-term complications such as incisional hernias and endocrine or exocrine pancreatic 
insufficiency.15,17 
Our study does not have the preferred design of a randomized trial and it is therefore possible that 
hidden confounding factors may have influenced results. For instance, the included cohorts did not 
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capture data on preoperative imaging, such as extent and location of peripancreatic necrosis on 
computed tomography. Theoretically, these factors may have influenced the decisions to perform 
minimally invasive or open necrosectomy. Small and centrally located peripancreatic collections may 
be more easily accessible by endoscopy whereas collections extending to the paracolic gutter may 
prefer a surgical approach. Notably, not all patients with necrotizing pancreatitis are candidates for 
minimally invasive techniques. A small minority of patients with extensive collections may only be 
suitable for open surgical approach. There may also be hidden confounders associated with the time 
period in which necrosectomy was performed: e.g. supportive treatment on the intensive care may 
have improved over the years. Unfortunately, year of necrosectomy could not be included as variable 
in the propensity score matching because patients treated by primary open necrosectomy largely 
originated from the older cohorts included in our study. We did, however, compensate for this possible 
time effect by including study cohort as a variable in the prediction model used to stratify patients 
according to their risk of death. A randomized trial with a sample size large enough to detect a 
difference in mortality will be very difficult to realize and no such trial is currently planned. Large 
observational studies therefore yield the best available evidence to guide clinical decision making in 
this severe and complex disease. Because patients from 51 hospitals across eight countries and three 
continents were included in this study, we believe our results are generalizable to patient populations 
with necrotizing pancreatitis worldwide.  
In conclusion, among severely ill patients with necrotizing pancreatitis, minimally invasive surgical 
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Shown are actual death rates for patients undergoing minimally invasive surgical necrosectomy (Panel A) and endoscopic necrosectomy (Panel B) as 
compared with patients undergoing open necrosectomy in unmatched cohorts and propensity-score matched cohorts. Patients are stratified in four risk groups 
based on predicted death at baseline (Low: <5%, Intermediate: ≥5% to <15%, High: ≥15% to <35% and Very high: ≥35%) which was determined by a 




Table 1. Baseline characteristics before and after propensity-score matching of patients undergoing minimally invasive surgical necrosectomy or open necrosectomy.* 































 %  
Low risk of death (< 5%)       
   Male sex - no. (%)  65 (68) 276 (73) 12.7  63 (72) 61 (70) 4.1  
   Age 43 ± 12 44 ± 13 9.5 44 ± 12 45 ± 14 5.7  
   Cause - no. (%)       
Gallstones 50 (51) 111 (29) 46.2  40 (46) 38 (44) 5.5  
Alcohol 28 (29) 177 (47) 38.0  28 (32) 27 (31) 1.5  
Other 19 (20) 89 (24) 9.7  19 (22) 22 (25) 8.0  
   APACHE-II score† 6.0 ± 3.4 7.7 ± 4.2 47.0  6.3 ± 3.4 6.0 ± 3.7 6.3  
      Cardiovascular failure - no. (%)†|| 0 (0) 7 (2) 19.7  0 (0) 0 (0) 0  
      Pulmonary failure - no. (%)†‡ 3 (3) 30 (8) 21.2  3 (3) 3 (3) 0.5  
      Renal failure - no. (%)†¶ 2 (2) 10 (3) 4.2  2 (2) 2 (2) 3.9  
   Documented infected necrosis - no. (%)£ 88 (91) 279 (74) 47.0  79 (90) 79 (90) 0.6  
   Tertiary referral - no. (%) 77 (80) 205 (55) 56.3  68 (78) 68 (78) 1.2  
































Intermediate risk of death (≥ 5% to < 15%)       
   Male sex - no. (%) 82 (69) 229 (67) 5.1  74 (69) 73 (68) 2.0  
   Age 54 ± 15 53 ± 14 5.9  54 ± 14 55 ± 13 6.2  
   Cause - no. (%)       
Gallstones 65 (55) 139 (40) 29.2  56 (52) 53 (49) 5.3  
Alcohol 29 (24) 119 (35) 23.0  28 (26) 30 (28) 3.3  
Other 25 (21) 85 (25) 9.6  24 (22) 25 (23) 2.6  
   APACHE-II score† 7.9 ± 3.0 10.0 ± 4.1 57.9  8.2 ± 2.8 8.1 ± 3.5 4.6  
      Cardiovascular failure - no. (%)†|| 3 (3) 65 (19) 53.2  3 (3) 3 (3) 5.8  
      Pulmonary failure - no. (%)†‡ 8 (7) 113 (33) 68.1 8 (8) 6 (6) 8.4  
      Renal failure - no. (%)†¶ 5 (4) 42 (12) 29.7  5 (5) 4 (4) 6.0  
   Documented infected necrosis - no. (%)£ 95 (80) 270 (79) 3.2  87 (81) 88 (82) 2.0  
   Tertiary referral - no. (%) 95 (80) 208 (61) 43.3  84 (78) 82 (76) 4.3  
   Time since hospital admission - days 48 ± 41 30 ± 27 50.0  43 ± 33 41 ± 36  5.1  
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High risk of death (≥ 15% to < 35%)       
   Male sex - no. (%) 65 (54) 140 (62) 17.5 43 (61) 44 (63) 4.1 
   Age 57 ± 13 58 ± 14 7.1 59 ± 13 59 ± 14 4.2 
   Cause - no. (%)       
Gallstones 72 (60) 88 (39) 43.0 35 (50) 36 (51) 1.7 
Alcohol 31 (25) 81 (36) 23.2 21 (30) 21 (30) 0.6 
Other 17 (15) 56 (25) 26.3 14 (20) 13 (19) 3.0 
   APACHE-II score† 10.1 ± 4.3 12.8 ± 4.2 62.2 11.3 ± 3.9 11.2 ± 3.5 0.9 
      Cardiovascular failure - no. (%)†|| 25 (21) 98 (44) 51.2 20 (29) 22 (31) 4.3 
      Pulmonary failure - no. (%)†‡ 25 (21) 145 (65) 97.6 23 (32) 24 (34) 4.8 
      Renal failure - no. (%)†¶ 7 (6) 65 (29) 64.7 7 (10) 7 (10) 2.8 
   Documented infected necrosis - no. (%)£ 97 (81) 182 (81) 0.5 60 (85) 61 (87) 3.3 
   Tertiary referral - no. (%) 99 (83) 160 (71) 27.4 58 (83) 58 (83) 0.4 































 %  
Very high risk of death (≥ 35%)       
   Male sex - no. (%) 81 (62) 146 (66) 8.2 68 (62) 70 (63) 2.6 
   Age 63 ± 12 62 ± 14 5.5 62 ± 12 63 ± 13 0.9 
   Cause - no. (%)       
Gallstones 74 (56) 99 (44) 23.7 62 (56) 66 (60) 7.3 
Alcohol 37 (29) 66 (30) 2.3 30 (27) 29 (26) 1.2 
Other 20 (15) 57 (26) 26.8 19 (17) 16 (14) 8.5 
   APACHE-II score† 16.8 ± 5.7 16.6 ± 5.3 3.3 17.0 ± 5.7 17.1 ± 5.5 1.2 
      Cardiovascular failure - no. (%)†|| 91 (69) 179 (81) 25.9 81 (74) 84 (76) 5.8 
      Pulmonary failure - no. (%)†‡ 90 (69) 182 (82) 30.9 79 (72) 78 (70) 2.0 
      Renal failure - no. (%)†¶ 59 (45) 123 (55) 21.0 53 (48) 50 (45) 4.4 
   Documented infected necrosis - no. (%)£ 123 (94) 154 (69) 67.3 103 (93) 105 (95) 7.5 
   Tertiary referral - no. (%) 115 (88) 168 (76) 31.4 95 (86) 92 (83) 5.4 




* Plus-minus values are means ± SD. A value of less than 10.0% of the standardized difference indicates a negligible difference between groups. Patients are 
stratified in four risk groups based on predicted death at baseline which was determined by a multivariable prediction model incorporating study cohort, 
APACHE-II score, cardiovascular failure, pulmonary failure, and renal failure in the 24 hours before necrosectomy (details on prediction model in appendix p 
6). 
† within 24 hours before necrosectomy. 
|| Circulatory systolic blood pressure <90 mm Hg, despite adequate fluid resuscitation, or need for inotropic catecholamine support. 
‡ PaO2 <60 mm Hg, despite FIO2 of 30%, or need for mechanical ventilation. 
¶ Creatinine level >177 μmol/liter after rehydration or need for hemofiltration or hemodialysis. 




Table 2. Baseline characteristics before and after propensity-score matching of patients undergoing endoscopic necrosectomy or open necrosectomy.* 

























 %  
Low risk of death (< 5%)       
   Male sex - no. (%) 22 (71) 276 (73) 5.3 21 (72) 21 (72) 1.4 
   Age 39 ± 11 44 ± 13 49.4 39 ± 11 40 ± 10 1.1 
   Cause - no. (%)       
Gallstones 10 (32) 111 (29) 6.3 8 (28) 8 (28) 0.3 
Alcohol 8 (26) 177 (47) 45.2 8 (28) 8 (28) 0.3 
Other 13 (42) 89 (24) 39.8 13 (44) 13 (44) 0.1 
   APACHE-II score† 3.3 ± 2.9 7.7 ± 4.2 124.8 3.7 ± 2.9 3.1 ± 2.8 10.0 
      Cardiovascular failure - no. (%)†|| 0 7 (2) 19.5 0 0 0 
      Pulmonary failure - no. (%)†‡ 0 30 (8) 42.4 0 0 0 
      Renal failure - no. (%)†¶ 0 10 (3) 23.4 0 0 0 
   Documented infected necrosis - no. (%)£ 12 (39) 279 (74) 76.5 11 (38) 12 (41) 8.4 
   Tertiary referral - no. (%) 25 (81) 205 (55) 57.8 23 (79) 23 (79) 3.2 


























Intermediate risk of death (≥ 5% to < 15%)       
   Male sex - no. (%) 85 (71) 229 (67) 9.2 49 (68) 48 (67) 2.4 
   Age 50 ± 14 53 ± 14 2.1 53 ± 14 54 ± 13 3.6 
   Cause - no. (%)       
Gallstones 57 (48) 139 (40) 14.3 33 (46) 34 (47) 1.2 
Alcohol 29 (24) 119 (35) 23.4 20 (28) 21 (29) 3.1 
Other 34 (28) 85 (25) 8.0 19 (26) 17 (24) 4.7 
   APACHE-II score† 6.5 ± 3.1 10.0 ± 4.1 96.7 7.4 ± 2.8 7.4 ± 3.6 0.5 
      Cardiovascular failure - no. (%)†|| 0 65 (19) 68.1 0 0 0 
      Pulmonary failure - no. (%)†‡ 1 (1) 113 (33) 94.5 1 (1) 1 (1) 6.7 
      Renal failure - no. (%)†¶ 0 42 (12) 52.9 0 0 0 
   Documented infected necrosis - no. (%)£ 59 (49) 270 (79) 64.3 46 (64) 47 (65) 3.1 
   Tertiary referral - no. (%) 80 (67) 208 (61) 12.8 46 (64) 45 (63) 1.0 
   Time since hospital admission – days 48 ± 51 30 ± 27 42.9 36 ± 30 37 ± 29 2.9 
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High risk of death (≥ 15% to < 35%)       
   Male sex - no. (%) 68 (51) 140 (62) 22.9 23 (58) 25 (63) 9.2 
   Age 59 ± 12 58 ± 14 6.0 60 ± 13 60 ± 14 1.5 
   Cause - no. (%)       
Gallstones 66 (50) 88 (39) 21.5 16 (40) 18 (45) 5.1 
Alcohol 27 (20) 81 (36) 35.8 13 (32) 12 (30) 3.5 
Other 40 (30) 56 (25) 11.7 11 (28) 10 (25) 2.8 
   APACHE-II score† 8.9 ± 2.9 12.8 ± 4.2 105.2 10.6 ± 2.8 10.5 ± 2.7 5.4 
      Cardiovascular failure - no. (%)†|| 11 (8) 98 (44) 88.2 9 (23) 10 (25) 4.5 
      Pulmonary failure - no. (%)†‡ 7 (5) 145 (65) 158.9 7 (18) 7 (18) 1.5 
      Renal failure - no. (%)†¶ 2 (2) 65 (29) 82.6 2 (5) 3 (8) 6.2 
   Documented infected necrosis - no. (%)£ 76 (57) 182 (81) 53.3 32 (80) 32 (80) 2.7 
   Tertiary referral - no. (%) 96 (72) 160 (71) 2.1 29 (73) 31 (78) 9.3 

























 %  
Very high risk of death (≥ 35%)       
   Male sex - no. (%) 40 (65) 146 (66) 2.3 37 (65) 35 (61) 5.0 
   Age 64 ± 14 62 ± 14 10.9 63 ± 14 63 ± 14 0.4 
   Cause - no. (%)       
Gallstones 37 (60) 99 (44) 30.6 34 (59) 33 (58) 0.6 
Alcohol 14 (22) 66 (30) 16.1 14 (25) 13 (23) 4.6 
Other 11 (18) 57 (26) 19.7 9 (16) 11 (19) 5.3 
   APACHE-II score† 16.0 ± 6.2 16.6 ± 5.3 11.9 16.2 ± 6.4 16.4 ± 5.3 2.8 
      Cardiovascular failure - no. (%)†|| 33 (53) 179 (81) 60.5 33 (58) 34 (60) 4.3 
      Pulmonary failure - no. (%)†‡ 35 (56) 182 (82) 57.6 35 (61) 34 (60) 1.3 
      Renal failure - no. (%)†¶ 18 (29) 123 (55) 55.3 18 (32) 16 (28) 6.2 
   Documented infected necrosis - no. (%)£ 50 (81) 154 (69) 26.8 46 (81) 46 (81) 0.2 
   Tertiary referral - no. (%) 48 (77) 168 (76) 3.8 45 (79) 43 (76) 6.7 




* Plus-minus values are means ± SD. A value of less than 10.0% of the standardized difference indicates a negligible difference between groups. Patients are 
stratified in four risk groups based on predicted death at baseline which was determined by a multivariable prediction model incorporating study cohort, 
APACHE-II score, cardiovascular failure, pulmonary failure, and renal failure in the 24 hours before necrosectomy (details on prediction model in appendix p 
6). 
† within 24 hours before necrosectomy. 
|| Circulatory systolic blood pressure <90 mm Hg, despite adequate fluid resuscitation, or need for inotropic catecholamine support. 
‡ PaO2 <60 mm Hg, despite FIO2 of 30%, or need for mechanical ventilation. 
¶ Creatinine level >177 μmol/liter after rehydration or need for hemofiltration or hemodialysis. 
£ Positive microbiological culture from fine-needle aspiration before necrosectomy or from first catheter drainage before necrosectomy or from primary 
necrosectomy. 
 
 
 
